• Clinuvel won Health Canada clearance to market SCENESSE (afamelanotide) to prevent phototoxicity in adults with erythropoietic protoporphyria.
• The Notice of Compliance gives Clinuvel commercial rights in Canada, extending prior authorizations in Europe, the US, and Australia.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clinuvel Pharmaceuticals Limited published the original content used to generate this news brief on July 13, 2026, and is solely responsible for the information contained therein.